
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has demonstrated strong operational momentum, with centers fully transitioned to the gen 5 system experiencing over a 20% volume increase in the first half of 2025 compared to the same period in 2024. The company is poised for further improvement in gross margins as its product mix shifts towards the gen 5 IPG, which is expected to enhance profitability and support top-line growth projected at 12-13% year-over-year in FY2026. Additionally, Inspire's strategic initiatives to broaden patient awareness and increase sales and marketing efforts contribute to a positive outlook, reflected by a revenue increase to $207.2 million for the most recent quarter, exceeding estimates and highlighting robust performance in both the U.S. and international markets.
Bears say
Inspire Medical Systems Inc has lowered its fiscal year 2025 revenue guidance by approximately $37.5 million, which has resulted in a significant downgrade in earnings per share expectations, from a range of $2.20-$2.30 to $0.40-$0.50, reflecting about a $1.20 impact on EPS. The gross margin of 84.0% fell short of previous estimates, compounded by an operational expenditure that was about $7 million higher than expected, indicating increased costs amid a challenging transition from the generation 4 to generation 5 system. The magnitude of these guidance revisions has led to a negative outlook for the company, with shares indicated to decline over 20% in after-hours trading, as the adjustment has raised concerns about ongoing revenue growth potential and the company’s operational efficiency.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares